Advances in understanding the mechanisms of anti-androgen ther-apeutic action and failure in castration-resistant prostate cancer
10.3969/j.issn.1000-8179.2015.20.967
- VernacularTitle:抗雄激素药物治疗去势抵抗型前列腺癌的机制研究进展
- Author:
Qianben WANG
;
Dayong WU
- Publication Type:Journal Article
- Keywords:
castration-resistant prostate cancer;
androgen receptor;
anti-androgen;
molecular mechanisms
- From:
Chinese Journal of Clinical Oncology
2015;(20):1002-1006
- CountryChina
- Language:Chinese
-
Abstract:
Castration-resistant prostate cancer (CRPC) is the lethal form of prostate cancer with developed resistance to androgen deprivation therapy. However, anti-androgen therapy remains an important treatment option because androgen receptor activation is a major driver of the advanced phase of CRPC. Drug resistance is frequently manifested despite the development of various novel anti-an-drogens with significant clinical efficacy. This review introduces several drugs prevalently used to treat CRPC. The mechanisms of ac-tion and pathways to resistance of these drugs are also discussed.
